Abstract��OBJECTIVE To introduce the pharmaceutical care for one patient with severe infection caused by Rhizopus spp after kidney transplantation which achieved a better therapeutic effect. METHODS According to the activity of zygomycetous, clinical pharmacists recommended the patient using posaconazole to treat Rhizopus spp infection which has less kidney injury. Clinical pharmacists optimized the treatment schemes with considering the pathophysiological conditions of the patient , the pharmacokinetic characteristics of the drug and metabolic drug interactions. RESULTS The Rhizopus spp infection was controlled using posaconazole oral suspension 200mg qid mixed with enteral nutrition. According to adjust the amount of tacrolimus by the plasma concentration and CYP3A5 genotype test result ,the tacrolimus concentration was most time maintained 4.8-6.7 ��g��L-1 during the treatment ,which ensure the safety of the transplanted kidney. The diarrhea was reduced by adjusting the methods of taking posaconazole, reducing the dose of mycophenolate and adding microecologics. CONCLUSIONS Drug treatment is generally complex for the patient with severe infection after renal transplantation. So, clinical pharmacists can carry out pharmaceutical care for such special patients for safety and effectiveness, through therapeutic drug monitoring and knowledge of pharmacokinetics to promote such patients to get the optimal drug treatment.
��������Ӣ����ϼ��������. 1������ֲ�������ظ�ù����Ⱦ���߸���ҩ�����Ƶ�ҩѧ����[J]. �й�ҩѧ��־, 2017, 52(2): 162-166.
PENG Huai-dong, LIU Ying, FENG Xia, WANG Ruo-lun. Pharmaceutical Care of Complicated Drug Treatment for One Patient with Severe Infection Caused by Rhizopus spp after Kidney Transplantation. Chinese Pharmaceutical Journal, 2017, 52(2): 162-166.
HU Z Q, ZHAO J Y, FANG W, et al. Retrospective analysis of hepatitis complicated with zygomycosis in mainland China : a review of 19 cases. Chin J Mycol(�й����ѧ��־), 2015, 10 (1): 31-34.
CORNELY O A, ARIKAN-AKDAGLI S, DANNAOUI E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect, 2014, 20 (3): 5-26.
WANG S B, WAN Z, LI R Y, et al. In vitro activity of posaconazole against 43 clinical isolates of zygomycetous fungi by E-test. Chin J Mycol(�й����ѧ��־),2012, 7 (3): 142-145.
Antibiotic Guidelines 2015-2016: Treatment Recommendations For Adult Inpatients. 2015:1-164.
COURTNEY R, SANSONE A, SMITH W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol, 2005, 45(2):185-192.
MA X, ZHAO L,WANG X X, et al. Advances in research on pharmacokinetic characteristics and therapeutic drug monitoring for the antifungal extended-spectrum posaconazole. Chin Pharm J(�й�ҩѧ��־), 2016, 51(6):433-436.
COURTNEY R, PAI S, LAUGHLIN M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother ,2003,47(9): 2788-2795.
EZZET F, WEXLER D, COURTNEY R, et al. Oral bioavailability of posaconazole in fasted healthy subjects. Clin Pharmacokinet ,2005,44 (2): 211-220.
KRISHNA G, MOTON A, MA L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother, 2009, 53(3): 958-966. WEXLER D, COURTNEY R, RICHARDS W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci, 2004, 21(5):645-653. RAAD I I, GRAYBILL J R, BUSTAMANTE A B, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis, 2006 ,42(12):1726-1734. SANSONE-PARSONS A, KRISHNA G, MARTINHO M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy, 2007, 27(6): 825-834. FENG G W, GUO T, LI J F, et al. CYP3A5 gene polymorphism and individualized administration of tacrolimus after kidney transplantation. Chin J Organ Transplant (�л�������ֲ��־), 2013, 34 (13): 647-650. SUN W, GUO H B, XIE Z L, et al. Association factors analysis of diarrhea in patients receiving kidney transplantation. J Peking Univ Health Sci (������ѧѧ��:ҽѧ��), 2013,45(5):779-781. SPAD O F,GERHARDT J,GUIMA ES T,et al. Incidence of diarrhea by clostridium difficile in hematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death. Rev Inst Med Trop Sao Paulo,2014,56(4): 325-331. KNECHT H, NEULINGER S C, HEINSEN F A, et al. Effects of ��-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to clostridium difficile associated diarrhea. PLoS One, 2014, 9(2): e89417. doi: 10. 1371/journal. pone. 0089417. SI J G, SUN M. Application of microecological modulators in prevention of antibiotic-associated diarrhea . J China Pharm(�й�ҩ��), 2014,25(38):3624-3626.